The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
Age ≥ 1 with a diagnosis of Still's Disease
Fever ≥ 38°C attributed to Still's Disease activity and documented for a number of days prior to Day 1 or
Rash attributed to Still's Disease activity or
Musculoskeletal involvement: arthritis in a number of joints per ACP criteria for active joint or
Patients out of weight range
Ongoing or previous treatment with immunomodulatory drugs
A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study
Glucocorticoid dose exceeding a set limit